An Open-label, Prospective Interventional Study of the Tolerability and Efficacy of Oral Harnalidge OCAS (Tamsulosin) 0.4 mg in Patients Who Are Unsatisfied With the Treatment of Tamsulosin 0.2 mg

Trial Profile

An Open-label, Prospective Interventional Study of the Tolerability and Efficacy of Oral Harnalidge OCAS (Tamsulosin) 0.4 mg in Patients Who Are Unsatisfied With the Treatment of Tamsulosin 0.2 mg

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Sep 2016

At a glance

  • Drugs Tamsulosin (Primary)
  • Indications Benign prostatic hyperplasia; Lower urinary tract symptoms
  • Focus Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 16 Sep 2016 Primary endpoint has been met, (Changes from baseline in total scores of International Prostate Symptom Score (IPSS)), according to the results published.
    • 16 Sep 2016 Efficacy and safety results (n=100) presented at the 46th Annual Meeting of the International Continence Society.
    • 13 Nov 2015 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top